{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:17:25Z","timestamp":1793830645253,"version":"4.6.1"},"reference-count":89,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1097\/adm.0000000000000045","type":"journal-article","created":{"date-parts":[[2014,9,12]],"date-time":"2014-09-12T10:47:05Z","timestamp":1410518825000},"page":"315-326","source":"Crossref","is-referenced-by-count":237,"title":["A Review of Buprenorphine Diversion and Misuse"],"prefix":"10.1097","volume":"8","author":[{"given":"Michelle R.","family":"Lofwall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon L.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210126","doi-asserted-by":"crossref","first-page":"427","DOI":"10.5694\/j.1326-5377.2005.tb06764.x","article-title":"Fungal endophthalmitis in intravenous drug users injecting buprenorphine contaminated with oral Candida species.","volume":"182","author":"Aboltins","year":"2005","journal-title":"Med J Aust"},{"key":"R2-3-20210126","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0376-8716(00)00141-1","article-title":"Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans.","volume":"61","author":"Amass","year":"2001","journal-title":"Drug Alcohol Depend"},{"key":"R3-3-20210126","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1001\/jama.280.22.1936","article-title":"Effective medical treatment of opiate addiction.","volume":"280","year":"1998","journal-title":"JAMA"},{"key":"R4-3-20210126","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.drugalcdep.2006.09.012","article-title":"Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users.","volume":"88","author":"Alho","year":"2007","journal-title":"Drug Alcohol Depend"},{"key":"R5-3-20210126","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/adc.63.1.81","article-title":"Maternal narcotic abuse and the newborn.","volume":"63","author":"Alroomi","year":"1988","journal-title":"Arch Dis Child"},{"key":"R7-3-20210126","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1080\/10550490490440780","article-title":"French field experience with buprenorphine.","volume":"13","author":"Auriacombe","year":"2004","journal-title":"Am J Addict"},{"key":"R8-3-20210126","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jama.285.1.39","article-title":"Deaths attributable to methadone vs buprenorphine in France.","volume":"285","author":"Auriacombe","year":"2001","journal-title":"JAMA"},{"key":"R9-3-20210126","first-page":"24","article-title":"A urinanalysis-based comparative study of treatment adherence on buprenorphine and buprenorphinenaloxone combination used as opioid substitution treatment.","volume":"9","author":"Balhara","year":"2012","journal-title":"Innov Clin Neurosci"},{"key":"R10-3-20210126","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s11606-006-0050-y","article-title":"Patient satisfaction with primary care office-based buprenorphinenaloxone treatment.","volume":"22","author":"Barry","year":"2007","journal-title":"J Gen Intern Med"},{"key":"R11-3-20210126","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/ADM.0b013e3182034e31","article-title":"Illicit use of buprenorphinenaloxone among injecting and noninjecting opioid users.","volume":"5","author":"Bazazi","year":"2011","journal-title":"J Addict Med"},{"key":"R12-3-20210126","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/j.1360-0443.2010.03014.x","article-title":"The global diversion of pharmaceutical drugs: opiate treatment and the diversion of pharmaceutical opiates: a clinicians perspective.","volume":"105","author":"Bell","year":"2010","journal-title":"Addiction"},{"key":"R13-3-20210126","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0168-8278(00)00049-0","article-title":"Hepatitis after intravenous buprenorphine misuse in heroin addicts.","volume":"34","author":"Berson","year":"2001","journal-title":"J Hepatol"},{"key":"R14-3-20210126","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s002130051096","article-title":"Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients.","volume":"46","author":"Bickel","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"key":"R15-3-20210126","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0196-9781(00)00252-7","article-title":"Agonistic effects of the opioid buprenorphine on the nociceptinOFQ receptor.","volume":"21","author":"Bloms-Funke","year":"2000","journal-title":"Peptides"},{"key":"R16-3-20210126","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1521-0391.2009.00002.x","article-title":"Methadone and buprenorphine toxicity in children.","volume":"19","author":"Boyer","year":"2010","journal-title":"Am J Addict"},{"key":"R17-3-20210126","doi-asserted-by":"crossref","first-page":"S197","DOI":"10.1086\/508184","article-title":"Buprenorphine use: the international experience.","volume":"43","author":"Carrieri","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R18-3-20210126","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/bjo.86.8.940","article-title":"Presumed ocular candidiasis in drug misusers after intravenous use of oral high dose buprenorphine (Subutex).","volume":"86","author":"Cassoux","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"R19-3-20210126","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.drugalcdep.2012.07.007","article-title":"Prescription medication exchange patterns among methadone maintenance patients.","volume":"127","author":"Caviness","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"R23-3-20210126","doi-asserted-by":"crossref","first-page":"302","DOI":"10.5055\/jom.2007.0018","article-title":"Use and misuse of buprenorphine in the management of opioid addiction.","volume":"3","author":"Cicero","year":"2007","journal-title":"J Opioid Manag"},{"key":"R24-3-20210126","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1360-0443.2009.02843.x","article-title":"Abuse liability of intravenous buprenorphinenaloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers.","volume":"105","author":"Comer","year":"2010","journal-title":"Addiction"},{"key":"R27-3-20210126","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/j.1526-4637.2010.00877.x","article-title":"Post-marketing surveillance of methadone and buprenorphine in the United States.","volume":"11","author":"Dasgupta","year":"2010","journal-title":"Pain Med"},{"key":"R28-3-20210126","doi-asserted-by":"crossref","first-page":"161","DOI":"10.5694\/j.1326-5377.2009.tb02729.x","article-title":"Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation.","volume":"191","author":"Degenhardt","year":"2009","journal-title":"Med J Aust"},{"key":"R31-3-20210126","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jsat.2004.06.005","article-title":"Consensus statement on office-based treatment of opioid dependence using buprenorphine.","volume":"27","author":"Fiellin","year":"2004","journal-title":"J Subst Abuse Treat"},{"key":"R32-3-20210126","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1056\/NEJMoa055255","article-title":"Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence.","volume":"355","author":"Fiellin","year":"2006","journal-title":"N Engl J Med"},{"key":"R34-3-20210126","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/fcp.12024","article-title":"OPPIDUM surveillance program: 20 years of information on drug abuse in France.","volume":"27","author":"Frauger","year":"2013","journal-title":"Fundam Clin Pharmacol"},{"key":"R35-3-20210126","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jsat.2004.03.002","article-title":"Network therapy: decreased secondary opioid use during buprenorphine maintenance.","volume":"26","author":"Galanter","year":"2004","journal-title":"J Subst Abuse Treat"},{"key":"R36-3-20210126","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.pnpbp.2010.12.002","article-title":"Supervised daily consumption, contingent take-home incentive and non-contingent take-home in methadone maintenance.","volume":"35","author":"Gerra","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R37-3-20210126","first-page":"121","article-title":"Is opioid substitution treatment beneficial if injecting behaviour continues Drug Alcohol D","volume":"133","author":"Gjersing","year":"2013","journal-title":"epend"},{"key":"R38-3-20210126","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2105\/AJPH.2007.123257","article-title":"Beyond abuse and exposure: framing the impact of prescription-medication sharing.","volume":"98","author":"Goldsworthy","year":"2008","journal-title":"Am J Public Health"},{"key":"R39-3-20210126","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1177\/000331979905000711","article-title":"Acute hand ischemia secondary to intraarterial buprenorphine injection: treatment with iloprost and dextran-40a case report.","volume":"50","author":"Gouny","year":"1999","journal-title":"Angiology"},{"key":"R40-3-20210126","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/toxsci\/65.1.107","article-title":"Buprenorphine and midazolam act in combination to depress respiration in rats.","volume":"65","author":"Gueye","year":"2002","journal-title":"Toxicol Sci"},{"key":"R41-3-20210126","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00228-011-1122-4","article-title":"Benzodiazepines and alcohol are associated with cases of fatal buprenorphine poisoning.","volume":"68","author":"Hakkinen","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"R42-3-20210126","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1477-7517-10-24","article-title":"Diversion of methadone or buprenorphine: harm versus helping.","volume":"10","author":"Havnes","year":"2013","journal-title":"Harm Reduct J"},{"key":"R43-3-20210126","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1097\/00042737-200410000-00013","article-title":"Acute hepatitis due to buprenorphine administration.","volume":"16","author":"Herve","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R44-3-20210126","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/00952990902939719","article-title":"Pulmonary hypertension in first episode infective endocarditis among intravenous buprenorphine users: case report.","volume":"35","author":"Ho","year":"2009","journal-title":"Am J Drug Alcohol Abuse"},{"key":"R45-3-20210126","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1046\/j.1360-0443.1998.9310155312.x","article-title":"Assessing the relationship between maternal opiate use and antepartum haemorrhage.","volume":"93","author":"Hulse","year":"1998","journal-title":"Addiction"},{"key":"R46-3-20210126","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0376-8716(03)00055-3","article-title":"From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States.","volume":"70","author":"Jaffe","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"R47-3-20210126","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.drugalcdep.2011.07.019","article-title":"Diversion and abuse of buprenorphine: findings from national surveys of treatment patients and physicians.","volume":"120","author":"Johanson","year":"2012","journal-title":"Drug Alcohol Depend"},{"key":"R49-3-20210126","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1176\/ajp.2007.164.5.797","article-title":"A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial.","volume":"164","author":"Kakko","year":"2007","journal-title":"Am J Psychiatry"},{"issue":"6","key":"R50-3-20210126","doi-asserted-by":"crossref","first-page":"e1700","DOI":"10.1542\/peds.2012-1342","article-title":"Buprenorphine may not be as safe as you think: a pediatric fatality from unintentional exposure.","volume":"130","author":"Kim","year":"2012","journal-title":"Pediatrics"},{"key":"R51-3-20210126","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1080\/10550490490440744","article-title":"Buprenorphine for office-based practice: consensus conference overview.","volume":"13","author":"Kosten","year":"2004","journal-title":"Am J Addict"},{"key":"R52-3-20210126","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/ADM.0b013e3182312983","article-title":"Statement of the American Society of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction.","volume":"5","author":"Kraus","year":"2011","journal-title":"J Addict Med"},{"key":"R53-3-20210126","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.drugalcdep.2011.04.002","article-title":"Post-marketing surveillance of buprenorphine-naloxone in Australia: diversion, injection and adherence with supervised dosing.","volume":"118","author":"Larance","year":"2011","journal-title":"Drug Alcohol Depend"},{"key":"R54-3-20210126","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1465-3362.2010.00283.x","article-title":"Definitions related to the use of pharmaceutical opioids: extramedical use, diversion, non-adherence and aberrant medication-related behaviours.","volume":"30","author":"Larance","year":"2011","journal-title":"Drug Alcohol Rev"},{"key":"R55-3-20210126","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.drugalcdep.2013.12.005","article-title":"The diversion and injection of a buprenorphine-naloxone soluble film formulation.","volume":"136","author":"Larance","year":"2014","journal-title":"Drug Alcohol Depend"},{"key":"R56-3-20210126","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.jpeds.2013.06.058","article-title":"Root causes, clinical effects, and outcomes of unintentional exposures to buprenorphine by young children.","volume":"163","author":"Lavonas","year":"2013","journal-title":"J Pediatr"},{"key":"R57-3-20210126","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.drugalcdep.2012.12.009","article-title":"A randomised controlled trial of sublingual buprenorphine-naloxone film versus tablets in the management of opioid dependence.","volume":"131","author":"Lintzeris","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"R58-3-20210126","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.drugalcdep.2012.05.025","article-title":"Inability to access buprenorphine treatment as a risk factor for using diverted buprenorphine.","volume":"126","author":"Lofwall","year":"2012","journal-title":"Drug Alcohol Depend"},{"key":"R59-3-20210126","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jsat.2011.04.008","article-title":"Efficacy of continuing medical education to reduce the risk of buprenorphine diversion.","volume":"41","author":"Lofwall","year":"2011","journal-title":"J Subst Abuse Treat"},{"key":"R60-3-20210126","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1521-0391.2009.00026.x","article-title":"Pharmacy willingness to partner with office-based opioid dependence treatment providers in conducting random buprenorphine pill counts.","volume":"19","author":"Lofwall","year":"2010","journal-title":"Am J Addict"},{"key":"R61-3-20210126","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1479-828X.2004.00221.x","article-title":"Obstetric and perinatal outcomes in pregnancies associated with illicit substance abuse.","volume":"44","author":"Ludlow","year":"2004","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"R62-3-20210126","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.drugalcdep.2004.08.011","article-title":"Buprenorphine treatment for opioid dependence: the relative efficacy of daily, twice and thrice weekly dosing.","volume":"77","author":"Marsch","year":"2005","journal-title":"Drug Alcohol Depend"},{"key":"R63-3-20210126","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2174\/157488611794480034","article-title":"Accidental and non-accidental ingestion of methadone and buprenorphine in childhood: a single center experience, 1999-2009.","volume":"6","author":"Martin","year":"2011","journal-title":"Curr Drug Saf"},{"key":"R64-3-20210126","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1001\/jama.284.13.1689","article-title":"Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation.","volume":"284","author":"McLellan","year":"2000","journal-title":"JAMA"},{"key":"R65-3-20210126","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s002130050804","article-title":"Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers.","volume":"141","author":"Mendelson","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"key":"R66-3-20210126","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1111\/j.1360-0443.2011.03424.x","article-title":"The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphinenaloxone tablets in opioid abusers.","volume":"106","author":"Middleton","year":"2011","journal-title":"Addiction"},{"key":"R67-3-20210126","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.2165\/11536020-000000000-00000","article-title":"Intravenous misuse of buprenorphine: characteristics and extent among patients undergoing drug maintenance therapy.","volume":"30","author":"Moratti","year":"2010","journal-title":"Clin Drug Invest"},{"key":"R68-3-20210126","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0376-8716(89)90013-6","article-title":"Psychoactive substance use and related behaviours of 135 regular illicit drug users in Scotland.","volume":"23","author":"Morrison","year":"1989","journal-title":"Drug Alcohol Depend"},{"key":"R70-3-20210126","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3109\/10826080009147699","article-title":"Drug dependence and death: survival analysis of the Baltimore ECA sample from 1981-1995.","volume":"35","author":"Neumark","year":"2000","journal-title":"Subst Use Misuse"},{"key":"R71-3-20210126","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/pds.2263","article-title":"Misuse of buprenorphine maintenance treatment since introduction of its generic forms: OPPIDUM survey.","volume":"21","author":"Nordmann","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R72-3-20210126","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1097\/PCC.0b013e3181f3a118","article-title":"Toddlers requiring pediatric intensive care unit admission following at-home exposure to buprenorphinenaloxone.","volume":"12","author":"Pedapati","year":"2011","journal-title":"Pediatr Crit Care Med"},{"key":"R73-3-20210126","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1742-7843.2008.00273.x","article-title":"Effects of various combinations of benzodiazepines with buprenorphine on arterial blood gases in rats.","volume":"103","author":"Pirnay","year":"2008","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R74-3-20210126","first-page":"261","article-title":"Substance use characteristics and treatment perceptions among opioid dependent pregnant women initiating methadone treatment.","volume":"111","author":"Quigley","year":"2013","journal-title":"J Kentucky Med Assoc"},{"key":"R75-3-20210126","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1046\/j.1360-0443.1998.93913859.x","article-title":"Six deaths linked to concomitant use of buprenorphine and benzodiazepines.","volume":"93","author":"Reynaud","year":"1998","journal-title":"Addiction"},{"key":"R76-3-20210126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/bdrc.20119","article-title":"Tobacco and pregnancy: overview of exposures and effects.","volume":"84","author":"Rogers","year":"2008","journal-title":"Birth Defects Res C Embryo Today"},{"key":"R77-3-20210126","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.drugalcdep.2007.04.006","article-title":"Sublingual buprenorphinenaloxone precipitated withdrawal in subjects maintained on 100 mg of daily methadone.","volume":"90","author":"Rosado","year":"2007","journal-title":"Drug Alcohol Depend"},{"key":"R78-3-20210126","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.drugalcdep.2008.03.025","article-title":"Buprenorphine in primary care: risk factors for treatment injection and implications for clinical management.","volume":"97","author":"Roux","year":"2008","journal-title":"Drug Alcohol Depend"},{"key":"R80-3-20210126","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2105\/AJPH.2012.301049","article-title":"Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009.","volume":"103","author":"Schwartz","year":"2013","journal-title":"Am J Public Health"},{"key":"R81-3-20210126","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.forsciint.2012.03.016","article-title":"Toxicological and pathological findings in a series of buprenorphine related deaths. Possible risk factors for fatal outcome.","volume":"220","author":"Selden","year":"2012","journal-title":"Forensic Sci Int"},{"key":"R82-3-20210126","first-page":"1","article-title":"A five-year follow-up of buprenorphine abuse potential.","volume":"1","author":"Simojoki","year":"2013","journal-title":"J Alcohol Drug Depend"},{"key":"R83-3-20210126","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1600-0447.1992.tb03224.x","article-title":"Cases of buprenorphine abuse in India.","volume":"86","author":"Singh","year":"1992","journal-title":"Acta Psychiatr Scand"},{"key":"R84-3-20210126","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/sj.clpt.6100508","article-title":"Contingency management: utility in the treatment of drug abuse disorders.","volume":"83","author":"Stitzer","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"R85-3-20210126","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s002130000637","article-title":"Effects of buprenorphinenaloxone in opioid-dependent humans.","volume":"154","author":"Stoller","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"key":"R86-3-20210126","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000320576","article-title":"Barriers to opioid substitution treatment access, entry and retention: a survey of opioid users, patients in treatment, and treating and non-treating physicians.","volume":"17","author":"Stover","year":"2011","journal-title":"Eur Addict Res"},{"key":"R87-3-20210126","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0022-3565(25)11174-9","article-title":"Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers.","volume":"261","author":"Strain","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"R88-3-20210126","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s002130050066","article-title":"Effects of buprenorphine versus buprenorphinenaloxone tablets in non-dependent opioid abusers.","volume":"148","author":"Strain","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"key":"R89-3-20210126","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0376-8716(01)00161-2","article-title":"Buprenorphine prescription by general practitioners in a French region.","volume":"65","author":"Thirion","year":"2002","journal-title":"Drug Alcohol Depend"},{"key":"R90-3-20210126","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1521-0391.2011.00186.x","article-title":"Compliance with buprenorphine medication-assisted treatment and relapse to opioid use.","volume":"21","author":"Tkacz","year":"2012","journal-title":"Am J Addict"},{"key":"R91-3-20210126","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/jat\/22.6.430","article-title":"Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities.","volume":"22","author":"Tracqui","year":"1998","journal-title":"J Anal Toxicol"},{"key":"R92-3-20210126","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0376-8716(02)00229-6","article-title":"Comparing homeless and domiciled pregnant substance dependent women on psychosocial characteristics and treatment outcomes.","volume":"69","author":"Tuten","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"R93-3-20210126","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.drugpo.2013.02.004","article-title":"First insights into community pharmacy based buprenorphine-naloxone dispensing in Finland.","volume":"24","author":"Uosukainen","year":"2013","journal-title":"Int J Drug Policy"},{"key":"R94-3-20210126","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.drugalcdep.2013.06.022","article-title":"Mortality among clients seeking treatment for buprenorphine abuse in Finland.","volume":"133","author":"Uosukainen","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"R95-3-20210126","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.drugalcdep.2012.07.002","article-title":"Twelve-year trend in treatment seeking for buprenorphine abuse in Finland.","volume":"127","author":"Uosukainen","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"R96-3-20210126","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.drugalcdep.2010.03.014","article-title":"Injection of buprenorphine and buprenorphinenaloxone tablets in Malaysia.","volume":"111","author":"Vicknasingam","year":"2010","journal-title":"Drug Alcohol Depend"},{"key":"R97-3-20210126","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0376-8716(02)00312-5","article-title":"Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France.","volume":"69","author":"Vidal-Trecan","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"R98-3-20210126","first-page":"135","article-title":"Practice-based buprenorphine maintenance treatment (BMT): how do French healthcare providers manage the opiate-addicted patients J Subst Abuse T","volume":"21","author":"Vignau","year":"2001","journal-title":"reat"},{"key":"R99-3-20210126","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1378\/chest.78.1.90","article-title":"Self-induced pulmonary granulomatosis. A consequence of intravenous injection of drugs intended for oral use.","volume":"78","author":"Waller","year":"1980","journal-title":"Chest"},{"key":"R100-3-20210126","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/BF02246290","article-title":"Effects of buprenorphine and methadone in methadone-maintained subjects.","volume":"119","author":"Walsh","year":"1995","journal-title":"Psychopharmacology (Berl)"},{"key":"R101-3-20210126","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/clpt.1994.71","article-title":"Clinical pharmacology of buprenorphine: ceiling effects at high doses.","volume":"55","author":"Walsh","year":"1994","journal-title":"Clin Pharmacol Ther"}],"container-title":["Journal of Addiction Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ADM.0000000000000045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T16:11:03Z","timestamp":1746375063000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01271255-201409000-00003"}},"subtitle":["The Current Evidence Base and Experiences From Around the World"],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":89,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/adm.0000000000000045","relation":{},"ISSN":["1932-0620"],"issn-type":[{"value":"1932-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]}}}